Dr. Shefali Miglani is one of the most successful myopia doctors I know, and she opened our conversation by telling me she failed. She presented the lens, the tech and the topography map, and parents walked out without signing up.

AI that predicts ten years of eye growth from one retinal photo. Our panel on Dr. David Ng's report from Vision China 2026 — and what it says about how far behind we are.

This is one of three stories from this month's Myopia News Monthly, alongside a study on late-onset myopia in high schoolers and a new RCT on red light therapy.

Full episode: myopiamindset.substack.com

Dr. Jennifer Lyerly walks through the STAR study numbers, the parents who just want the glasses, and the 25-year-old nobody knows what to do with.

Dr. Carrie Hartigan on building a pediatric-only practice, training a myopia coordinator, winning pediatrician referrals, and why one flat fee changed how she treats every kid.

Dr. David Ng was a happy general practice OD in 2002. Then he put a retinoscope in front of his three-year-old son.

The AMA takes a stand on myopia. When does the back optic zone actually matter? Sydnexis gets a second shot.

Dr. Cary Herzberg on why the surprise rejection stung, what the advisory committee will weigh, and why an approved drop changes everything for preventive eye care.

He inherited a handful of poorly-fit ortho-K patients, gave himself six months to master the specialty, and ended up co-founding a lens design company. Dr. Sukh Gill returns for a deep-dive interview.

Here’s a question Dr. Cary Herzberg wants every optometrist to ask in the mirror: if you dropped every vision care plan tomorrow, could your practice survive?

The "high myopia as disease" debate, atropine + ortho-k combo therapy, and axial length as standard of care.

For all the noise around artificial intelligence, the most useful question for a myopia practice isn’t “Will this replace me?” It’s “Can this help me do the work I already know I should be doing?”

HHS and the Surgeon General issue a warning on children’s screen use. The FDA rejects Sydnexis’ SYD-101 — despite the STAR trial meeting its primary endpoint. Hoya’s MiYOSMART iQ posts some of the strongest myopia control data ever reported.

Dr. Cary Herzberg — 40+ years in specialty optometry — on the insurance model burning doctors out, the specialty care exit ramp, and whether the profession can save itself.

Dr. Marie Homa-Palladino on Listening, Connection, and Myopia Management Done Right

Every month there’s more happening in myopia management than any one clinician can keep up with — new studies, new products, new debates. We go through the five most important stories from Q1 2026 — and we don’t hold back on the disagreements.

Dr. Cary Herzberg lays down four decades of frustration: optometry has had the data, the products, and the patients in the chair since the early 1980s — and is still, in 2026, asking how to get colleagues to start.

Twenty years ago, the myopia toolbox had one drawer: ortho-K. Today, U.S. optometrists have FDA-approved soft contacts, an approved spectacle lens, off-label low-dose atropine, and a steady drip of next-generation options coming through Health Canada first. So how do you actually decide what to put a kid in?

The Sydnexis SYD-101 FDA rejection: the data the regulator ignored, the kids it leaves behind, and what you can actually do about it.

What does it look like to build a full-spectrum myopia management program inside one of the country’s top pediatric hospitals — and what can every optometrist learn from it?